• Abdel Fattah S, Abdel KhaliK K, el-Shawarby L, Abdel Fattah S, el Shimi S, Soliman M, Hassan H. Some immunological aspects of chronic liver diseases in Egyptian children. J. Egypt. Soc. Parasitol. 21: 343-355 (1991).

• Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 99: 1316-1320 (2004). *

• Akiyama Y, Tanaka M, Takeishi M, Adachi D, Mimori A, Suzuki T. Clinical, serological and genetic study in patients with CREST syndrome. Intern. Med. 39: 451-456 (2000). *

• Al-Jabri AA, Al Belushi MS, Nsanze H. Frequency and levels of autoantibodies in healthy adult Omanis. Ann. Saudi Med. 23: 372-375 (2003).

• Al-Osaimi AM, Berg CL. Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature. Am. J. Gastroenterol. 97: S85 (2002). *

• Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, Bonkovsky HL. Autoimmune hepatitis triggered by statins. J. Clin. Gastroenterol. 40: 757-776 (2006)..

• Allen S, Huber J, Devendra D. Prevalence of organ-specific autoantibodies in childhood- and adult-onset type 1 diabetes. Ann. N. Y. Acad. Sci. 1150: 260-262 (2008). *

• Alric L, Thebault S, Selves J, Peron JM, Mejdoubi S, Fortenfant F, Vinel JP. Characterization of overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis according to antimitochondrial antibodies status. Gastroenterol. Clin. Biol. 31: 11-16 (2007). *

• Alvarez F. Clinical and diagnostics aspects in children. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 87-88 (2004). *

• Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72: 1084-1091 (2002). *

• Anthony A, Sim R, Guillaume JL, Strosberg AD, Dhillon AP, Pounder RE, Wakefield AJ. Beta(beta)3-adrenergic receptors in human pancreatic islet and duodenal somatostatin neuroendocrine cells. Aliment. Pharmacol. Ther. 14: 579-585 (2000). *

• Arcavi M, Orfus G. Prevalence of antinuclear envelope antibodies and their isotypes in sera positive for antinuclear antibodies. Medicina (B. Aires) 66: 327-331 (2006).

• Asahina K, Tsai SY, Li P, Ishii M, Maxson RE Jr, Sucov HM, Tsukamoto H. Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology 49: 998-1011 (2009).

• Asawa S, Saito T, Satoh A, Ohtake K, Tsuchiya T, Okada H, Neilson EG, Gotoh M. Participation of bone marrow cells in biliary fibrosis after bile duct ligation. J. Gastroenterol. Hepatol. 22: 2001-2008 (2007). *

• Assem ES, Peh KH, Wan BY, Middleton BJ, Dines J, Marson CM. Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction. Int. Immunopharmacol. 8: 1793-1801 (2008).

• Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, Sarzi-Puttini P. Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. Autoimmunity 41: 87-91 (2008).

• Aubert V, Graf Pisler I, Spertini F. Improved diagnoses of autoimmune hepatitis using an anti-actin ELISA. J. Clin. Lab. Anal. 22: 340-345 (2008).

• Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J. Pediatr. Gastroenterol. Nutr. 45: 222-227 (2007). *

• Bachem MG, Schunemann M, Ramadani M, Siech M, Beger H, Buck A, Zhou S, Schmid-Kotsas A, Adler G. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128: 907-921 (2005). *

• Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, Miller YI. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein. Toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ. Res. 104: 210-218 (2009). *

• Bakker-Jonges LE, ter Borg PC, van Buuren HR, Hooijkaas H. A retrospective study on the role of antibodies against soluble liver antigen (anti-SLA antibodies) and other autoantibodies in the diagnostics of autoimmune hepatitis. Ned. Tijdschr. Geneeskd. 150: 490-494 (2006).

• Berg PA, Klein R. Autoimmune hepatitis and overlap syndrome: diagnosis. Schweiz. Rundsch. Med. Prax. 91: 1339-1346 (2002).

• Bianchi FB, Muratori L. Primary and secondary autoimmunity in hepatology. Ann. Ital. Med. Int. 15: 56-62 (2000).

• Biasi D, Caramasch P, Carletto A, Casaril M, Colombari R, Zeminian S, Bambara LM. Sjogren's syndrome associated with autoimmune hepatitis. A case report. Clin. Rheumatol. 16: 409-412 (1997).

• Bielecka-Dabrowa A, Barylski M, Mikhailidis DP, Rysz J, Banach M. HSP 70 and atherosclerosis - protector or activator? Expert Opin. Ther. Targets 13: 307-317 (2009).

• Bittencourt PL, Farias AQ, Abrantes-Lemos CP, Goncalves LL, Goncalves PL, Magalhaes EP, Carrilho FJ, Laudanna AA, Cancado EL. Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 19: 873-878 (2004). *

• Bittencourt PL, Goldberg AC, Cancado EL, Porta G, Carrilho FJ, Farias AQ, Palacios SA, Chiarella JM, Abrantes-Lemos CP, Baggio VL, Laudanna AA, Kalil J. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am. J. Gastroenterol. 94: 1906-1913 (1999). *

• Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, Schrumpf E. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 23: 1369-1376 (1996). *

• Bogdanos D, Vergani D, Mieli-Vergani G. Overlap syndromes from pediatrics to adulthood. J. Gastroenterol. Hepatol. 19: S284-S286 (2004). *

• Bogdanos DP, Bianchi I, Ma Y, Mitry RR, Mieli-Vergani G, Vergani D. Targets of antibodies to soluble liver antigen in patients with autoimmune hepatitis. Clin. Chem. 50: 682-683 (2004). *

• Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J. Gastroenterol. 14: 3374-3387 (2008). *

• Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin. Liver Dis. 29: 241-253 (2009).

• Bonaci-Nikolic B, Andrejevic S, Radlovic N, Davidovic I, Sofronic L, Spuran M, Micev M, Nikolic MM. Serological and clinical comparison of children and adults with anti-endomysial antibodies. J. Clin. Immunol. 27: 163-171 (2007). *

• Brazowski E, Dotan I, Tulchinsky H, Filip I, Eisenthal A. Galectin-3 expression in pouchitis in patients with ulcerative colitis who underwent ileal pouch-anal anastomosis (IPAA). Pathol. Res. Pract. 205: 551-558 (2009).

• Broome U. Autoimmune hepatitis and overlap syndromes. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 38-39. September 12 - 13 (2003). *

• Burt AD. Spectrum of liver pathology in immune mediated liver diseases. J. Gastroenterol. Hepatol. 19: S353-S355 (2004). *

• Bustos D, Moret A, Tambutti M, Gogorza S, Testa R, Ascione A, Prigoshin N. Autoantibodies in Argentine women with recurrent pregnancy loss. Am. J. Reprod. Immunol. 55: 201-207 (2006). *

• Caballeria L, Pares A, Rodes J. Treatment of primary biliary cirrhosis. Contributions to Science 1: 79-85 (1999). *

• Caglar E, Ugurlu S, Ozenoglu A, Can G, Kadioglu P, Dobrucali A. Autoantibody frequency in celiac disease. Clinics (Sao Paulo) 64: 1195-1200 (2009). *

• Cao W, Fiocchi C, Pricolo VE. Production of interleukin-1beta, hydrogen peroxide, and nitric oxide by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am. J. Physiol. Cell. Physiol. 289: C1408-C1416 (2005). *

• Carroccio A, Giannitrapani L, Soresi M, Not T, Iacono G, Di Rosa C, Panfili E, Notarbartolo A, Montalto G. Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease. Gut 49: 506-511 (2001). *

• Cassani F, Fusconi M, Bianchi FB, Selleri L, Baffoni L, Lenzi M, Pisi E. Precipitating antibodies to rabbit thymus extractable antigens in chronic liver disease: relationship with anti-actin antibodies. Clin. Exp. Immunol. 68: 588-595 (1987). *

• Cavill D, Waterman SA, Gordon TP. Antibodies raised against the second extracellular loop of the human muscarinic M3 receptor mimic functional autoantibodies in Sjogren's syndrome. Scand. J. Immunol. 59: 261-266 (2004). *

• Cha S, Singson E, Cornelius J, Yagna JP, Knot HJ, Peck AB. Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjogren's syndrome-associated autoantibodies. J. Rheumatol. 33: 296-306 (2006).

• Chatterjee S, Vrolix G, Van Marck E, Vanderwinden JM. The distribution of interstitial cells of cajal in the ileum is not altered by infection with Schistosoma mansoni. J. Vector Borne Dis. 44: 90-97 (2007).

• Chava KR, Karpurapu M, Wang D, Bhanoori M, Kundumani-Sridharan V, Zhang Q, Ichiki T, Glasgow WC, Rao GN. CREB-mediated IL-6 expression is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol. 29: 809-815 (2009).

• Chazouilleres O. A case of autoimmune hepatitis. Gastroenterol. Clin. Biol. 33: F36-F43 (2009).

• Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28: 296-301 (1998). *

• Cho DH, Choi MS, Kim DH, Kim do Y, Shim SG, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC. A prospective study on the prevalence and clinical significance of autoantibodies in patients with suspected nonalcholic fatty liver disease. Korean J. Hepatol. 11: 261-267 (2005).

• Chon CY, Park JY. Primary biliary cirrhosis. Korean J. Hepatol. 12: 364-372 (2006).

• Chretien-Leprince P, Ballot E, Andre C, Olsson NO, Fabien N, Escande A, Oksman F, Dubuquoi S, Jego S, Goetz J, Chevailler A, Sanmarco M, Humbel RL, Johanet C. Diagnostic value of anti-F-actin antibodies in a French multicenter study. Ann. N. Y. Acad. Sci. 1050: 266-273 (2005). *

• Clancy RM, Zheng P, O'Mahony M, Izmirly P, Zavadil J, Gardner L, Buyon JP. Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block. Arthritis Rheum. 56: 4120-4131 (2007). *

• Clemente MG, Musu MP, Frau F, Brusco G, Sole G, Corazza GR, De Virgiliis S. Immune reaction against the cytoskeleton in coeliac disease. Gut 47: 520-526 (2000). *

• Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J. Clin. Gastroenterol. 38: 801-804 (2004).

• Csepregi A, Szodoray P, Zeher M. Do autoantibodies predict autoimmune liver disease in primary Sjogren's syndrome? Data of 180 patients upon a 5 year follow-up. Scand. J. Immunol. 56: 623-629 (2002). *

• Czaja AJ. Autoantibodies in autoimmune liver disease. Adv. Clin. Chem. 40: 127-164 (2005).

• Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J. Hepatol. 30: 394-401 (1999). *

• Czaja AJ. The autoimmune hepatitis/hepatitis C overlap syndrome: does it exist? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 42-43. October 15-16 (2003). *

• Czaja AJ. Round table: classification of autoimmune liver diseases and diagnostic criteria. Subgroups of autoimmune hepatitis are irrelevant. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 58-59 (2004). *

• Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J. Hepatol. 51: 161-167 (2009).

• Czaja AJ. Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55 (2006). *

• Czaja AJ. Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1: 63-70 (1999).

• Czaja AJ. Autoimmune hepatitis: clinical and laboratory diagnosis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 52-54 (2004). *

• Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 26: 459-466 (1997). *

• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J. Hepatol. 24: 52-59 (1996). *

• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 18: 816-822 (1993).

• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J. Hepatol. 18: 342-352 (1993).

• Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24: 1068-1073 (1996). *

• Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 85: 713-717 (1983).

• Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am. J. Gastroenterol. 97: 413-419 (2002). *

• Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig. Dis. Sci. 40: 33-40 (1995).

• Czaja AJ, Manns MP. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am. J. Gastroenterol. 90: 1206-1211 (1995).

• Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J. Clin. Gastroenterol. 37: 315-329 (2003).

• Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig. Dis. Sci. 41: 1733-1740 (1996).

• Czaja AJ, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC, Donaldson PT. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J. Hepatol. 37: 302-308 (2002). *

• Czaja AJ, Taswell HF, Rakela J, Schimek C. Frequency of antibody to hepatitis C virus in asymptomatic HBsAg-negative chronic active hepatitis. J. Hepatol. 14: 88-93 (1992).

• da Rosa Utiyama SR, da Silva Kotze LM, Nisihara RM, Carvalho RF, de Carvalho EG, de Sena MG, de Messias Reason IJ. Spectrum of autoantibodies in celiac patients and relatives. Dig. Dis. Sci. 46: 2624-2630 (2001). *

• da Rosa Utiyama SR, Nisihara RM, Nass FR, Oliveira NP, Fiedler PT, de Messias-Reason IT. Autoantibodies in patients with Down syndrome: early senescence of the immune system or precocious markers for immunological diseases? J. Paediatr. Child. Health 44: 182-186 (2008). *

• Dalekos GN, Zachou K, Liaskos C, Gatselis N. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur. J. Intern. Med. 13: 293-303 (2002).

• Das KM. Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. J. Gastroenterol. Hepatol. 19: S290-S294 (2004). *

• Davalos M, Roman R, Bustios C, Zumaeta E, Yabar A. Autoimmune hepatitis: clinical forms and related factors to their response to treatment. Rev. Gastroenterol. Peru 24: 305-313 (2004).

• de Graaf R, Kloppenburg G, Kitslaar PJ, Bruggeman CA, Stassen F. Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect. 8: 1859-1865 (2006). *

• Deltenre P, Berson A, Marcellin P, Degott C, Biour M, Pessayre D. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut 44: 886-888 (1999). *

• Desai HG, Gupte PA. Increasing incidence of Crohn's disease in India: is it related to improved sanitation? Indian J. Gastroenterol. 24: 23-24 (2005). *

• Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3: 797-801 (1997).

• Djilali-Saiah I, Fakhfakh A, Louafi H, Caillat-Zucman S, Debray D, Alvarez F. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis. J. Hepatol. 45: 844-850 (2006). *

• Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J. Hepatol. 40: 904-909 (2004).

• Dorner T, Held C, Trebeljahr G, Lukowsky A, Yamamoto K, Hiepe F. Serologic characteristics in primary biliary cirrhosis associated with sicca syndrome. Scand. J. Gastroenterol. 29: 655-660 (1994).

• Dubel L, Farges O, Johanet C, Sebagh M, Bismuth H. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection. Transplantation 65: 1072-1075 (1998).

• Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J. Hepatol. 33: 163-166 (2000). *

• el-Shabrawi M, Wilkinson ML, Portmann B, Mieli-Vergani G, Chong SK, Williams R, Mowat AP. Primary sclerosing cholangitis in childhood. Gastroenterology 92: 1226-1235 (1987).

• Elshazly LB, Youssef AM, Mahmoud NH, Ibrahim MM. Study of non-standard auto-antibodies as prognostic markers in auto immune hepatitis in children. Ital. J. Pediatr. 35: 22 (2009). *

• Eroglu Y, Duzovali O, Kavukcu S, Irken G, Buyukgebiz B. Combination of steroid with azathioprine in treatment of giant cell autoimmune hepatitis. Turk. J. Pediatr. 39: 565-571 (1997).

• Etxagibel A, Julia MR, Brotons A, Company MM, Dolz C. Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. J. Med. Case Reports 2: 25 (2008). *

• European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51: 237-267 (2009). *

• Fabien N, Desbos A, Bienvenu J, Magdalou J. Autoantibodies directed against the UDP-glucuronosyltransferases in human autoimmune hepatitis. Autoimmun. Rev. 3: 1-9 (2004). *

• Fagoonee S, De Luca L, De Angelis C, Castelli A, Rizzetto M, Pellicano R. Anti-Saccharomyces cerevisiae as unusual antibodies in autoimmune hepatitis. Minerva Gastroenterol. Dietol. 55: 37-40 (2009).

• Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr. Opin. Gastroenterol. 20: 560-564 (2004).

• Feld J, Heathcote E. Epidemiology of autoimmune liver disease. J. Gastroenterol. Hepatol. 18: 1118-1128 (2003). *

• Ferreira AR, Roquete ML, Penna FJ, Toppa NH. Autoimmune hepatitis in children and adolescents: clinical study, diagnosis and therapeutic response. J. Pediatr. (Rio. J.) 78: 309-314 (2002). *

• Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481 (2006). *

• Fiducia M, Lauretta R, Lunghi R, Kyanvash S, Pallotti S. Hashimoto's thyroiditis and autoimmunity parameters: descriptive study. Minerva Med. 98: 95-99 (2007).

• Franco J, Saeian K. Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101 (1999).

• Frenzel C, Herkel J, Luth S, Galle PR, Schramm C, Lohse AW. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am. J. Gastroenterol. 101: 2731-2736 (2006). *

• Garcia Romero R, Martin de Carpi J, Bernal Cuartas C, Pinillos Pison S, Varea Calderon V. Autoimmune hepatitis in pediatric patients. Rev. Esp. Enferm. Dig. 99: 255-258 (2007).

• Garcia-Leiva J, Rios-Vaca A, Torre-Delgadillo A. Antibodies and physiopathogeny of autoimmune hepatitis. Rev. Invest. Clin. 55: 577-582 (2003).

• Garzelli C, Pacciardi A, Basolo F, Falcone G. Mechanisms other than polyclonal B cell activation possibly involved in Epstein-Barr virus-induced autoimmunity. Clin. Exp. Immunol. 76: 412-416 (1989). *

• Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, Wirth S. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha. World J. Gastroenterol. 12: 5787-5792 (2006). *

• Geng X, Biancone L, Dai HH, Lin JJ, Yoshizaki N, Dasgupta A, Pallone F, Das KM. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 114: 912-922 (1998). *

• Gheorghe L, Iacob S, Bolog N, Stoicescu A, Parvulescu I, Popescu I. Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis complicated by hepatocellular carcinoma. Case report. Rom. J. Gastroenterol. 13: 33-38 (2004).

• Ghonaim M, Al-Ghamdi A, El-Bana H, Bakr A, Ghoneim E, El-Edel R, Hassona M, Shoeib S, Allam H. Autoantibodies in chronic liver disease. Egypt. J. Immunol. 12: 101-111 (2005).

• Gogos CA, Nikolopoulou V, Zolota V, Siampi V, Vagenakis A. Autoimmune cholangitis in a patient with celiac disease: a case report and review of the literature. J. Hepatol. 30: 321-324 (1999). *

• Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G, Meyer zum Buschenfelde KH. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J. Hepatol. 24: 699-705 (1996). *

• Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am. J. Clin. Pathol. 114: 591-598 (2000). *

• Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F, Volta U, Ferri A, Lenzi M, Bianchi FB. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J. Clin. Pathol. 59: 280-284 (2006). *

• Granito A, Muratori P, Cassani F, Pappas G, Muratori L, Agostinelli D, Veronesi L, Bortolotti R, Petrolini N, Bianchi FB, Volta U. Anti-actin IgA antibodies in severe coeliac disease. Clin. Exp. Immunol. 137: 386-392 (2004). *

• Granito A, Muratori P, Ferri S, Pappas G, Quarneti C, Lenzi M, Bianchi FB, Muratori L. Diagnosis and therapy of autoimmune hepatitis. Mini Rev. Med. Chem. 9: 847-860 (2009).

• Greeve M, Ferrell L, Kim M, Combs C, Roberts J, Ascher N, Wright TL. Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes. Hepatology 17: 593-598 (1993).

• Gregorio GV, Davies ET, Mieli-Vergani G, Vergani D. Significance of extractable nuclear antigens in childhood autoimmune liver disease. Clin. Exp. Immunol. 102: 308-313 (1995). *

• Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 35: 515-519 (2002).

• Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33: 544-553 (2001). *

• Gregorio GV, Portmann B, Mowat AP, Vergani D, Mieli-Vergani G. A 12-year-old girl with antimitochondrial antibody-positive autoimmune hepatitis. J. Hepatol. 27: 751-754 (1997). *

• Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK. Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J. Gastroenterol. Hepatol. 16: 1144-1148 (2001). *

• Hamilton T, DeMatteo R, McClane S, Burke C, Rombeau J, Raper S. Adenoviral-mediated gene transfer to murine small intestine is more efficient in neonates than adults. J. Pediatr. Surg. 32: 373-377 (1997).

• Han S, Tredger M, Gregorio GV, Mieli-Vergani G, Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 21: 58-62 (1995).

• Hautekeete ML, Henrion J, Naegels S, DeNeve A, Adler M, Deprez C, Devis G, Kloppel G. Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. Liver 15: 25-29 (1995).

• Hay JE, Czaja AJ, Rakela J, Ludwig J. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 9: 193-197 (1989).

• Heim MH. Autoimmune hepatitis. Ther. Umsch. 61: 499-504 (2004).

• Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, Heaton ND, O'Grady JG. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 34: 464-470 (2001). *

• Hernandez HM, Kovarik P, Whitington PF, Alonso EM. Autoimmune hepatitis as a late complication of liver transplantation. J. Pediatr. Gastroenterol. Nutr. 32: 131-136 (2001). *

• Hirschfield GM, Al-Harthi N, Heathcote EJ. Review: current status of therapy in autoimmune liver disease. Ther. Adv. Gastroenterol. 2: 11-28 (2009). *

• Husby G, Skrede S, Blomhoff JP, Jacobsen CD, Berg K, Gjone E. Serum immunoglobulins and organ non-specific antibodies in diseases of the liver. Scand. J. Gastroenterol. 12: 297-304 (1977).

• Ikeda Y, Toda G, Hashimoto N, Aotsuka S, Yokohari R, Maruyama T, Oka H. Anticalmodulin autoantibody in liver diseases: a new antibody against a cytoskeleton-related protein. Hepatology 7: 285-293 (1987).

• Ingordo V, Gentile C, Iannazzone S, Cusano F, Naldi L. The 'EpiEnlist' project: a dermo-epidemiologic study on a representative sample of young Italian males. Prevalence of selected pigmentary lesions. J. Eur. Acad. Dermatol. Venereol. 21: 1091-1096 (2007). *

• Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, Podda M. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 25: 1090-1095 (1997). *

• Irving KS, Sen D, Tahir H, Pilkington C, Isenberg DA. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus - a retrospective review of cases. Rheumatology (Oxford) 46: 1171-1173 (2007). *

• Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *

• Izumi Y, Tanaka S, Hidaka Y, Shimaoka Y, Tatsumi KI, Takano T, Kaneko A, Oku K, Amino N. Relation between post-partum liver dysfunction and anti-cytochrome 2D6 antibodies. Am. J. Reprod. Immunol. 50: 355-362 (2003). *

• Jackson MW, Reed JH, Smith AJ, Gordon TP. An autoantibody in narcolepsy disrupts colonic migrating motor complexes. J. Neurosci. 28: 13303-13309 (2008).

• Jara LJ, Medina G, Vera-Lastra O. Systemic antiphospholipid syndrome and atherosclerosis. Clin. Rev. Allergy Immunol. 32: 172-177 (2007).

• Jaskowski TD, Konnick EQ, Ashwood ER, Litwin CM, Hill HR. Prevalence of IgG autoantibody against F-actin in patients suspected of having autoimmune or acute viral hepatitis. J. Clin. Lab. Anal. 21: 249-253 (2007).

• Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 35: 409-413 (2002). *

• Kagalwalla AF, Altraif I, Shamsan L, Omojola M, Khan H, Kagalwalla YA. Primary sclerosing cholangitis in Arab children: report of four cases and literature review. J. Pediatr. Gastroenterol. Nutr. 24: 146-152 (1997). *

• Kato T, Miyakawa H, Ishibashi M. Frequency and significance of anti-glutathione S-transferase autoantibody (anti-GST A1-1) in autoimmune hepatitis. J. Autoimmun. 22: 211-216 (2004).

• Kato Y, Suzuki K, Kumagai M, Nishimura K, Miyamori H, Kobayashi K, Hattori N, Nakanuma Y. Familial primary biliary cirrhosis. Immunological and genetic study. Am. J. Gastroenterol. 75: 188-191 (1981).

• Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappa B and induction of insulin-like growth factor-1 receptor. J. Biol. Chem. 283: 7754-7762 (2008). *

• Kawaguchi N, Miyakawa H, Abe K, Kitazawa E, Fujikawa H, Kikuchi K, Kako M, Shibata M, Shibuya A, Onozuka Y, Yoshida N, Ueno Y. Western blot analysis of anti-M2 antibodies in anti-mitochondrial antibody-negative primary biliary cirrhosis. Rinsho Byori 45: 1079-1084 (1997).

• Kaya S, Demirci M, Sesli Cetin E, Cicioglu Aridogan B, Sahin M, Tas T, Korkmaz M. Investigation of the presence of autoantibodies in patients with toxocariasis. Mikrobiyol. Bul. 43: 661-666 (2009).

• Kim HJ, Ham SA, Kim SU, Hwang JY, Kim JH, Chang KC, Yabe-Nishimura C, Kim JH, Seo HG. Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta. Circ. Res. 102: 193-200 (2008). *

• Kimura M, Tatsumi KI, Tada H, Ikemoto M, Fukuda Y, Kaneko A, Kato M, Hidaka Y, Amino N. Enzyme immunoassay for autoantibodies to human liver-type arginase and its clinical application. Clin. Chem. 46: 112-117 (2000). *

• Kiriyama K, Usui T, Takemura T, Ikeda K, Kishida H, Izumoto T, Kanayama Y, Hirota S. A case of rapid-onset antimitochondrial antibody-positive autoimmune hepatitis possibly triggered by a urinary tract infection. Nippon Shokakibyo Gakkai Zasshi 107: 270-277 (2010).

• Kitami N, Komada T, Ishii H, Shimizu H, Adachi H, Yamaguchi Y, Kitamura T, Oide H, Miyazaki A, Ishikawa M, et al. Immunological study of anti-M2 in antimitochondrial antibody-negative primary biliary cirrhosis. Intern. Med. 34: 496-501 (1995). *

• Klein R, Huizenga JR, Gips CH, Berg PA. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis before orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J. Hepatol. 20: 181-189 (1994).

• Kloppel G, Seifert G, Lindner H, Dammermann R, Sack HJ, Berg PA. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch. A. Pathol. Anat. Histol. 373: 143-160 (1977).

• Kryczka W, Walewska-Zielecka B, Dutkiewicz E. Acute seronegative hepatitis C manifesting itself as adult giant cell hepatitis - a case report and review of literature. Med. Sci. Monit. 9 Suppl. 3: 29-31 (2003).

• Kuloglu Z, Kirsaclioglu CT, Kansu A, Ensari A, Girgin N. Celiac disease: presentation of 109 children. Yonsei Med. J. 50: 617-623 (2009). *

• Kumar V, Beutner EH, Chorzelski TP. Antiendomysial antibody - useful serological indicator of dermatitis herpetiformis. Arch. Dermatol. Res. 279: 454-458 (1987).

• Kurki P, Miettinen A, Linder E, Pikkarainen P, Vuoristo M, Salaspuro MP. Different types of smooth muscle antibodies in chronic active hepatitis and primary biliary cirrhosis: their diagnostic and prognostic significance. Gut 21: 878-884 (1980). *

• Kurtovic J, Riordan S. Clinical aspects of primary biliary cirrhosis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 31-32. October 15-16 (2003). *

• Laadhar L, Zitouni M, Kallel-Sellami M, Bouguerra R, Chaabouni H, Makni S. Spectrum of autoantibodies in Tunisian adult type 1 diabetes mellitus. Ann. N. Y. Acad. Sci. 1107: 356-362 (2007). *

• Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Am. J. Gastroenterol. 90: 247-249 (1995).

• Ladefoged K, Andersen P, Jorgensen J. Autoantibodies and serum immunoglobulins in chronic liver diseases. Acta Med. Scand. 205: 103-109 (1979).

• Latella G, Sferra R, Vetuschi A, Zanninelli G, D'Angelo A, Catitti V, Caprilli R, Gaudio E. Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid. Eur. J. Clin. Invest. 38: 410-420 (2008).

• Latella G, Vetuschi A, Sferra R, Catitti V, D'Angelo A, Zanninelli G, Flanders KC, Gaudio E. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int. 29: 997-1009 (2009). *

• Latella G, Vetuschi A, Sferra R, Zanninelli G, D'Angelo A, Catitti V, Caprilli R, Flanders KC, Gaudio E. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur. J. Clin. Invest. 39: 145-156 (2009).

• Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol. Rep. 61: 22-32 (2009). *

• Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-Myb expression. J. Clin. Invest. 96: 2461-2468 (1995). *

• Lee WM, Shelton LL, Galbraith RM. Antibodies to hepatocyte membrane antigens in chronic liver disease: detection by immunofluorescence after Bouin's fixation. J. Histochem. Cytochem. 31: 1246-1249 (1983).

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Leibovitch L, George J, Levi Y, Bakimer R, Shoenfeld Y. Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Immunol. Lett. 48: 129-132 (1995).

• Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, Bianchi FB, Tiribelli C. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 45: 435-441 (1999). *

• Leuschner M, Holtmeier J, Ackermann H, Leuschner U. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur. J. Gastroenterol. Hepatol. 14: 1369-1376 (2002).

• Lim YS, Oh HB, Choi SE, Kwon OJ, Heo YS, Lee HC, Suh DJ. Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule. J. Hepatol. 48: 133-139 (2008). *

• Lindgren S, Manthorpe R, Eriksson S. Autoimmune liver disease in patients with primary Sjogren's syndrome. J. Hepatol. 20: 354-358 (1994).

• Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 31: 453-463 (2006).

• Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int. 28: 233-239 (2008). *

• Lollar K, Farrag TY, Cao D, Niparko J, Tufano RP. Langerhans cell histiocytosis of the thyroid gland. Am. J. Otolaryngol. 29: 201-204 (2008).

• Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM, Borsatti A, Bertolotti M, Cassani F, Bagni A, Muratori P, Ganazzi D, Bianchi FB, Carulli N. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig. Dis. Sci. 48: 2173-2181 (2003). *

• Lozano A, Vildosola H, Takano J, Vargas G, Uribe R, Moreno C. Clinical and immunological profile in 22 patients with primary biliary cirrhosis. Rev. Gastroenterol. Peru. 20: 14-24 (2000).

• Lu B, Alroy J, Luquetti AO, Pereiraperrin M. Human autoantibodies specific for neurotrophin receptors TrkA, TrkB, and TrkC protect against lethal Trypanosoma cruzi infection in mice. Am. J. Pathol. 173: 1406-1414 (2008). *

• Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type-2. Gastroenterology 130: 868-882 (2006). *

• Macak J. Antibodies against mitochondria and smooth muscle in primary biliary cirrhosis. Cesk. Patol. 12: 175-179 (1976).

• Mackay IR. Historical reflections on autoimmune hepatitis. World J. Gastroenterol. 14: 3292-3300 (2008). *

• Maggiore G, Riva S, Sciveres M. Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood. Minerva Gastroenterol. Dietol. 55: 53-70 (2009).

• Maggiore G, Sciveres M. Autoimmune hepatitis: a childhood disease. Current Pediatric Reviews 1: 73-90 (2005). *

• Maia JM, Maranhao HD, Sena LV, Rocha LR, Medeiros LA, Ramos AM. Hepatic stellate cell activation and hepatic fibrosis in children with type 1 autoimmune hepatitis: an immunohistochemical study of paired liver biopsies before treatment and after clinical remission. Eur. J. Gastroenterol. Hepatol. Dec 14 [Epub ahead of print] (2009).

• Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, Dalekos GN. Polyclonal hypergammaglobulinemia and high smooth-muscle autoantibody titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. Int. J. Infect. Dis. 13: e157-e160 (2009).

• Malaguarnera M, Guccione N, Musumeci S, Brogna A, Motta M, Di Fazio I. Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C. BioDrugs 18: 63-70 (2004).

• Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern. Emerg. Med. Jan 27 [Epub ahead of print] (2010).

• Manns M, Meyer zum Buschenfelde KH, Arnold W. The diagnostic value of immunologic findings in the differentiation of chronic liver diseases. Leber. Magen. Darm. 18: 290-292, 295, 298 (1988).

• Manns MP. Round table: classification of autoimmune liver diseases and diagnostic criteria. Subgroups of autoimmune hepatitis are important. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 56-57 (2004). *

• Marcinkiewicz M, Gryc E, Kreczko S. The role of selected serologic markers in the diagnosis of autoimmune hepatitis. Przegl. Lek. 55: 614-618 (1998).

• Marta S, Ewa NM, Miroslaw S, Marek S, Krzysztof L, Jan Z. The diagnostic problems in patient with ascites, elevated Ca 125 level and autoantibodies against nuclear antigens and smooth muscle antigens mimicking advanced ovarian carcinoma - case study. Ginekol. Pol. 79: 375-377 (2008).

• Martinez-Neira R, Dos Remedios CG, Mackay IR. An actin-myosin functional assay for analysis of smooth muscle (anti-microfilament) autoantibodies in human plasma. J. Immunol. Methods 338: 63-66 (2008). *

• Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Hamada S, Shimosegawa T. Fibrinogen induces cytokine and collagen production in pancreatic stellate cells. Gut 58: 550-559 (2009).

• Mathew J, Hines JE, Toole K, Johnson SJ, James OF, Burt AD. Quantitative analysis of macrophages and perisinusoidal cells in primary biliary cirrhosis. Histopathology 25: 65-70 (1994).

• Matos M, Capozzolo N, Golindano C, Gonzalez JC, Guirola E, Ramirez R, Machado I. Humoral immunologic changes in inflammatory colonic diseases. G. E. N. 47: 129-135 (1993).

• McFarlane IG. Autoimmune markers and their role in the pathogenesis of PSC. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 70. October 15-16 (2003). *

• McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am. J. Gastroenterol. 93: 777-784 (1998). *

• Mehendiratta V, Mitroo P, Bombonati A, Navarro VJ, Rossi S, Rubin R, Herrine SK. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin. Gastroenterol. Hepatol. 7: 98-103 (2009).

• Meliconi R, Stancari MV, Garagnani M, Baraldini M, Stefanini GF, Miglio F, Gasbarrini G. Occurrence and significance of IgG liver membrane autoantibodies (LMA) in chronic liver diseases of different aetiology. Clin. Exp. Immunol. 51: 565-571 (1983). *

• Meyer zum Buschenfelde KH. Immunology of liver diseases. Schweiz. Med. Wochenschr. 117: 1065-1075 (1987).

• Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, Palmer JM, Heathcote EJ. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis. Gut 35: 260-265 (1994). *

• Mieli-Vergani G, Heller S, Jara P, Vergani D, Chang MH, Fujisawa T, Gonzalez-Peralta RP, Kelly D, Mohan N, Shah U, Murray KF. Autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 49: 158-164 (2009).

• Mieli-Vergani G, Vergani D. Chapter 21. Unique aspects of autoimmune hepatitis in children. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 277-283 (2007). *

• Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH? Semin. Liver Dis. 29: 297-306 (2009).

• Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J. Gastroenterol. 14: 3360-3367 (2008). *

• Mieli-Vergani G, Vergani D. Approach to a child with chronic liver disease. J. Gastroenterol. Hepatol. 19: S377-S378 (2004). *

• Mieli-Vergani G, Vergani D. Autoimmune liver disease in children. Ann. Acad. Med. Singapore 32: 239-243 (2003). *

• Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin. Liver Dis. 18: 271-279 (1998).

• Mieli-Vergani G, Vergani D. Autoimmune liver disease - therapeutic aspects in children. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 89-91 (2004). *

• Mieli-Vergani G, Vergani D. Autoimmune liver disease in children. Pedgastro 2005 - Conference Abstracts. Pediatric Oncall [http://www.pediatriconcall.com/fordoctor/Conference_abstracts/autoimmune_liver_disease_in_children.asp] (2006).

• Mikata R, Yokosuka O, Imazeki F, Fukai K, Kanda T, Saisho H. Prolonged acute hepatitis A mimicking autoimmune hepatitis. World J. Gastroenterol. 11: 3791-3793 (2005). *

• Min JK, Han NI, Kim JA, Lee YS, Cho CS, Kim HY. A case of cholestatic autoimmune hepatitis and acute liver failure: an unusual hepatic manifestation of mixed connective tissue disease and Sjogren's syndrome. J. Korean Med. Sci. 16: 512-515 (2001). *

• Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am. J. Surg. Pathol. 28: 471-478 (2004).

• Mitry E, Algayres JP, Bili H, Coutant G, Gros P, Nizou JY, Castagne C, Vergeau B, Daly JP. Autoimmune cholangitis successfully treated with corticotherapy. One case. Gastroenterol. Clin. Biol. 22: 94-97 (1998).

• Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Okamoto R, Takaguchi K, Ikeda H, Makino Y, Ando M, Sakaguchi K, Yamamoto K. Clinical features of antinuclear antibodies-negative type 1 autoimmune hepatitis. Hepatol. Res. 39: 241-246 (2009). *

• Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, Yamamoto K. Clinical features of autoimmune hepatitis diagnosed based on simplified criteria of the International Autoimmune Hepatitis Group. Dig. Liver Dis. Jul 24 [Epub ahead of print] (2009).

• Miyake Y, Iwasaki Y, Takaki A, Kobashi H, Sakaguchi K, Shiratori Y. Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis. Intern. Med. 46: 1945-1950 (2007). *

• Miyake Y, Yamamoto K. Current status of autoimmune hepatitis in Japan. Acta Med. Okayama 62: 217-226 (2008). *

• Mizutani T, Akiho H, Khan WI, Murao H, Ogino H, Kanayama K, Nakamura K, Takayanagi R. Persistent gut motor dysfunction in a murine model of T-cell-induced enteropathy. Neurogastroenterol. Motil. Sep 7 [Epub ahead of print] (2009).

• Montes Santiago J, Gambon Deza F, Garcia Garcia MJ, Gonzalez Vazquez L, Hermo Brion JA, Perez Alvarez R. Usefulness of autoantibodies in the study of autoimmune liver diseases and prevalence of autoimmune extrahepatic manifestations. An. Med. Interna. 17: 343-346 (2000).

• Moon H, Noh J, Hur M, Yun Y, Lee CH, Kwon SY. High prevalence of autoantibodies in hepatitis A infection: the impact on laboratory profiles. J. Clin. Pathol. 62: 786-788 (2009).

• Mudawi HM, Yousif BA. Fulminant hepatic failure in an African setting: etiology, clinical course, and predictors of mortality. Dig. Dis. Sci. 52: 3266-3269 (2007). *

• Mueller T, Bianchi L, Menges M. Autoimmune hepatitis 2 years after the diagnosis of primary sclerosing cholangitis: an unusual overlap syndrome in a 17-year-old adolescent. Eur. J. Gastroenterol. Hepatol. 20: 232-236 (2008).

• Munoz LE, del Rocio Ayala SR. The clinical laboratory in the diagnosis of autoimmune liver diseases. Rev. Gastroenterol. Mex. 58: 164-169 (1993).

• Muratori L, Cassani F, Pappas G, Guidi M, Mele L, Lorenza V, Lenzi M, Bianchi FB, Muratori P. The hepatitic/cholestatic "overlap" syndrome: an Italian experience. Autoimmunity 35: 565-568 (2002).

• Muratori P, Granito A, Pappas G, Muratori L, Lenzi M, Bianchi FB. Autoimmune liver disease 2007. Mol. Aspects Med. 29: 96-102 (2007).

• Muratori P, Muratori L, Agostinelli D, Pappas G, Veronesi L, Granito A, Cassani F, Terlizzi P, Lenzi M, Bianchi FB. Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity 35: 497-500 (2002).

• Myrsky E, Syrjanen M, Korponay-Szabo IR, Maki M, Kaukinen K, Lindfors K. Altered small-bowel mucosal vascular network in untreated coeliac disease. Scand. J. Gastroenterol. 44: 162-167 (2009). *

• Nagasaki F, Ueno Y, Kanno N, Okamoto H, Shimosegawa T. A case of acute hepatitis with positive autoantibodies who actually had hepatitis E virus infection. Hepatol. Res. 32: 134-137 (2005).

• Nagasaki F, Ueno Y, Mano Y, Igarashi T, Yahagi K, Niitsuma H, Okamoto H, Shimosegawa T. A patient with clinical features of acute hepatitis E viral infection and autoimmune hepatitis. Tohoku J. Exp. Med. 206: 173-179 (2005). *

• Nakajima M, Shimizu H, Miyazaki A, Watanabe S, Kitami N, Sato N. Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis? J. Gastroenterol. 34: 607-612 (1999). *

• Nakajima S, Umebayashi H, Kurosawa R, Imagawa T, Katakura S, Mori M, Aihara Y, Yokota S, Sogo T, Inui A, Fujisawa T, Hanzawa N. A case of autoimmune hepatitis needed to be differentiated from EBV hepatitis, in that the histology of liver biopsy specimen was useful for diagnosis. Nihon Rinsho Meneki Gakkai Kaishi 28: 154-158 (2005).

• Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, Aoshima M, Hasegawa T, Makino I. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J. Gastroenterol. Hepatol. 13: 490-495 (1998).

• Nakamura RM, Chisari FV, Edgington TS. Laboratory tests for diagnosis of autoimmune diseases. Prog. Clin. Pathol. 6: 177-203 (1975).

• Nakanuma Y, Harada K, Kaji K, Terasaki S, Tsuneyama K, Moteki S, Van de Water J, Leung PS, Gershwin ME. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. Liver 17: 281-287 (1997).

• Nakayama S, Mukae H, Morisaki T, Sakamoto N, Ohba K, Abe K, Takeshima F, Mizuta Y, Ida H, Ozono Y, Kohno S. Sarcoidosis accompanied by systemic lupus erythematosus and autoimmune hepatitis. Intern. Med. 46: 1657-1661 (2007). *

• Nakazato Y, Yamaji Y, Oshima N, Hayashi M, Saruta T. Calcification and osteopontin localization in the peritoneum of patients on long-term continuous ambulatory peritoneal dialysis therapy. Nephrol. Dial. Transplant. 17: 1293-1303 (2002). *

• Nancey S, Blanvillain E, Parmentier B, Flourie B, Bayet C, Bienvenu J, Fabien N. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm. Bowel Dis. 11: 986-991 (2005). *

• Nardi N, Brito-Zeron P, Ramos-Casals M, Aguilo S, Cervera R, Ingelmo M, Font J. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjogren's syndrome. Prevalence and clinical significance in 335 patients. Clin. Rheumatol. 25: 341-346 (2006). *

• Narkewicz MR, Dell Olio D, Karpen SJ, Murray KF, Schwarz K, Yazigi N, Zhang S, Belle SH, Squires RH; Pediatric Acute Liver Failure Study Group. Pattern of diagnostic evaluation for the causes of pediatric acute liver failure: an opportunity for quality improvement. J. Pediatr. 155: 801-806.e1 (2009).

• Ohira H, Takiguchi J, Rai T, Shishido S, Sato Y. Two cases of primary biliary cirrhosis complicated with syringomyelia. Am. J. Gastroenterol. 98: 224-226 (2003). *

• Okazaki K. Clinical relevance of autoimmune-related pancreatitis. Best Pract. Res. Clin. Gastroenterol. 16: 365-378 (2002).

• Okazaki K, Uchida K, Ohana M, Nakase H, Uose S, Inai M, Matsushima Y, Katamura K, Ohmori K, Chiba T. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology 118: 573-581 (2000). *

• Oya H, Sato Y, Yamamoto S, Kobayashi T, Watanabe T, Kokai H, Hatakeyama K. De novo autoimmune hepatitis after living donor liver transplantation in a 25-day-old newborn baby: a case report. Transplant. Proc. 41: 433-434 (2009). *

• Ozen H, Kocak N, Saltik IN, Yuce A, Gurakan F. Autoimmune hepatitis. Indian J. Pediatr. 68: 725-728 (2001).

• Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, Daruich J, Findor J, Tanno H, Canero-Velasco C, Fainboim L. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 30: 1374-1380 (1999). *

• Parsons CJ, Bradford BU, Pan CQ, Cheung E, Schauer M, Knorr A, Krebs B, Kraft S, Zahn S, Brocks B, Feirt N, Mei B, Cho MS, Ramamoorthi R, Roldan G, Ng P, Lum P, Hirth-Dietrich C, Tomkinson A, Brenner DA. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology 40: 1106-1115 (2004). *

• Pathmakanthan S, Kay EW, Murray FE. Autoimmune chronic active hepatitis associated with the presence of antiphospholipid antibodies. Eur. J. Gastroenterol. Hepatol. 10: 155-157 (1998).

• Patriarca F, Skert C, Sperotto A, Zaja F, Falleti E, Mestroni R, Kikic F, Calistri E, Fili C, Geromin A, Cerno M, Fanin R. The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp. Hematol. 34: 389-396 (2006). *

• Pavic S, Simonovic J, Boricic I, Svirtlih N. Autoantibodies characteristic for autoimmune hepatitis found in chronic hepatitis C. Srp. Arh. Celok. Lek. 131: 437-442 (2003).

• Pedreira S, Sugai E, Moreno ML, Vazquez H, Niveloni S, Smecuol E, Mazure R, Kogan Z, Maurino E, Bai JC. Significance of smooth muscle/anti-actin autoantibodies in celiac disease. Acta Gastroenterol. Latinoam. 35: 83-93 (2005).

• Perez Garrigues H, Carmona E, Morera C, Sanchez-Cuenca JM. Circulating auto-antibodies in Meniere's disease. Ann. Otolaryngol. Chir. Cervicofac. 112: 225-228 (1995).

• Polenakovic M, Cukaranovic R, Savic V, Jovanovic I, Stefanovic V. Immunological studies in Balkan Endemic Nephropathy. Prilozi. 28: 13-22 (2007).

• Polman CH, Kappos L, Dahlke F, Graf R, Beckmann K, Bogumil T, Pozzilli C, Thompson AJ. Interferon beta-1b treatment does not induce autoantibodies. Neurology 64: 996-1000 (2005).

• Polte T, Fuchs L, Behrendt AK, Hansen G. Different role of CD30 in the development of acute and chronic airway inflammation in a murine asthma model. Eur. J. Immunol. 39: 1736-1742 (2009). *

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Poupon R, Chazouilleres O, Poupon RE. Chronic cholestatic diseases. J. Hepatol. 32: S129-S140 (2000).

• Qiu DK, Li XM, Wei J, Ye LJ, Peng YS, Ma X. Clinical features of 107 autoimmune hepatitis patients and 30 of them with AIH-primary biliary cirrhosis overlap syndrome. Zhonghua Gan Zang Bing Za Zhi 16: 367-371 (2008).

• Quaranta S, Shulman H, Ahmed A, Shoenfeld Y, Peter J, McDonald GB, Van de Water J, Coppel R, Ostlund C, Worman HJ, Rizzetto M, Tsuneyama K, Nakanuma Y, Ansari A, Locatelli F, Paganin S, Rosina F, Manns M, Gershwin ME. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin. Immunol. 91: 106-116 (1999). *

• Quismorio FP Jr, Kaufman RL, Beardmore T, Mongan ES. Reactivity of serum antibodies to the keratin layer of rat esophagus in patients with rheumatoid arthritis. Arthritis Rheum. 58: S69-S74 (2008). *

• Radlovic N, Janic D, Sajic S, Jankovic S, Jesic M, Lekovic Z, Petrovic R. IPEX syndrome - case report. Srp. Arh. Celok. Lek. 136: 538-541 (2008).

• Ramakrishna B, Eapen CE, Kang G, Kurian G, Chandy GM. Familial intrahepatic cholestatic cirrhosis with positive antimitochondrial antibody: familial primary biliary cirrhosis. J. Clin. Gastroenterol. 30: 255-258 (2000).

• Ramos-Casals M, Sanchez-Tapias JM, Pares A, Forns X, Brito-Zeron P, Nardi N, Vazquez P, Velez D, Arias I, Bove A, Plaza J, Rodes J, Font J. Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjogren's syndrome. J. Rheumatol. 33: 1593-1599 (2006).

• Randle HW, Millns JL, Schroeter AL, Winkelmann RK. Cutaneous immunofluorescence in primary biliary cirrhosis. JAMA 246: 1679-1681 (1981).

• Ren X, Shao H, Wei Q, Sun Z, Liu N. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J. Int. Med. Res. 37: 847-854 (2009).

• Romanelli RG, La Villa G, Almerigogna F, Vizzutti F, Di Pietro E, Fedi V, Gentilini P, Laffi G. Uveitis in autoimmune hepatitis: a case report. World J. Gastroenterol. 12: 1637-1640 (2006). *

• Romero-Gomez M, Wichmann I, Crespo J, Pares A, Rodrigo L, Alvarez A, Diago M, Pons-Romero F, Sanchez-Munoz D, Aguilar-Reina J, Andrade RJ, Salmeron J, Sanchez-Pobre P, Rebollo JM, Martin-Vivaldi R, Castellano-Megias V, Nunez-Roldan A, Bruguera M. Serum immunological profile in patients with chronic autoimmune cholestasis. Am. J. Gastroenterol. 99: 2150-2157 (2004). *

• Saadah OI, Smith AL, Hardikar W. Long-term outcome of autoimmune hepatitis in children. J. Gastroenterol. Hepatol. 16: 1297-1302 (2001). *

• Saito H, Rai T, Takahashi A, Kanno Y, Monoe K, Irisawa A, Ohira H. Clinicolaboratory characteristics of Japanese patients with primary biliary cirrhosis-autoimmune hepatitis overlap. Fukushima J. Med. Sci. 52: 71-77 (2006).

• Salaspuro MP, Sipponen P, Ikkala E, Kolho L, Makkonen HM, Miettinen TA, Rasanen JA, Siurala M. Clinical correlations and significance of orceinpositivity in chronic active hepatitis and primary biliary cirrhosis. Ann. Clin. Res. 8: 206-215 (1976).

• Sanchez-Munoz D, Castellano-Megias VM, Romero-Gomez M. Expression of bcl-2 in ductular proliferation is related to periportal hepatic stellate cell activation and fibrosis progression in patients with autoimmune cholestasis. Dig. Liver Dis. 39: 262-266 (2007).

• Sarin SK, Monga R, Sandhu BS, Sharma BC, Sakhuja P, Malhotra V. Primary biliary cirrhosis in India. Hepatobiliary Pancreat. Dis. Int. 5: 105-109 (2006). *

• Sato Y, Harada K, Sudo Y, Watanabe K, Nakahama T, Morimoto H, Nakanuma Y. Autoimmune hepatitis associated with bile duct injury resembling chronic non-suppurative destructive cholangitis. Pathol. Int. 52: 478-482 (2002). *

• Satoh T, Hirakata M, Yoshida T, Matsumura M, Miyachi K, Mimori T, Akizuki M. Systemic lupus erythmatosus associated with autoimmune hepatitis two cases with novel autoantibodies to transfer RNA-related antigens. Clin. Rheumatol. 16: 305-309 (1997).

• Savige JA, Paspaliaris B, Silvestrini R, Davies D, Nikoloutsopoulos T, Sturgess A, Neil J, Pollock W, Dunster K, Hendle M. A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J. Clin. Pathol. 51: 568-575 (1998). *

• Sediva A, Cihakova D, Lebl J. Immunological findings in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and their family members: are heterozygotes subclinically affected? J. Pediatr. Endocrinol. Metab. 15: 1491-1496 (2002).

• Seo S, Toutounjian R, Conrad A, Blatt L, Tong MJ. Favorable outcomes of autoimmune hepatitis in a community clinic setting. J. Gastroenterol. Hepatol. 23: 1410-1414 (2008). *

• Shaoul R, Lerner A. Associated autoantibodies in celiac disease. Autoimmun. Rev. 6: 559-565 (2007).

• Sherlock S. Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis. Clin. Liver Dis. 4: 97-113 (2000).

• Shibata M, Morizane T, Tanaka A, Onozuka Y, Uchida T, Gershwin ME, Mitamura K. A case of autoimmune hepatitis with a high titer of antimitochondrial antibody and normal gamma-globulinemia. J. Gastroenterol. Hepatol. 16: 830-835 (2001). *

• Shimizu K, Kobayashi M, Tahara J, Shiratori K. Cytokines and peroxisome proliferator-activated receptor gamma ligand regulate phagocytosis by pancreatic stellate cells. Gastroenterology 128: 2105-2118 (2005). *

• Shinoda M, Tanaka Y, Kuno T, Matsufuji T, Matsufuji S, Murakami Y, Mizutani T. High levels of autoantibodies against drug-metabolizing enzymes in SLA/LP-positive AIH-1 sera. Autoimmunity 37: 473-480 (2004).

• Shiraoku H, Hokamura M, Sagara K, Fujiyama S. A case of primary sclerosing cholangitis. Gastroenterol. Jpn. 20: 368-373 (1985).

• Silveira MG, Lindor KD. Primary sclerosing cholangitis. Can. J. Gastroenterol. 22: 689-698 (2008). *

• Singh G, Palaniappan S, Rotimi O, Hamlin PJ. Autoimmune hepatitis triggered by hepatitis A. Gut 56: 304 (2007). *

• Smith AJ, Jackson MW, Wang F, Cavill D, Rischmueller M, Gordon TP. Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjogren syndrome. Hum. Immunol. 66: 411-416 (2005).

• Soares A, Cunha R, Rodrigues F, Ribeiro H. Smooth muscle autoantibodies with F-actin specificity. Autoimmun. Rev. 8: 713-716 (2009).

• Sobajima J, Ozaki S, Uesugi H, Osakada F, Inoue M, Fukuda Y, Shirakawa H, Yoshida M, Rokuhara A, Imai H, Kiyosawa K, Nakao K. High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis. Gut 44: 867-873 (1999). *

• Steele IL, Levy C, Lindor KD. Primary sclerosing cholangitis - approach to diagnosis. MedGenMed. 9: 20 (2007). *

• Storch WB. Autoimmune hepatitides - update 2004. Cell. Mol. Biol. (Noisy-le-grand) Suppl. 50: OL569-OL580 (2004).

• Strassburg CP. Autoimmune liver diseases. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 66-70 (2005). *

• Strassburg CP. Molecular characterization of autoantigens in liver diseases. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 30. September 12 - 13 (2003). *

• Strassburg CP, Manns MP. Chapter 8. Prevalence and significance of autoantibodies in acute and chronic liver diseases and hepatocellular carcinoma. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 95-110 (2007). *

• Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin. Liver Dis. 22: 339-352 (2002). *

• Sun J, Xu Y, Dai Z, Sun Y. Intermittent high glucose enhances proliferation of vascular smooth muscle cells by upregulating osteopontin. Mol. Cell. Endocrinol. 313: 64-69 (2009).

• Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am. J. Gastroenterol. 97: 1191-1197 (2002). *

• Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 108: 1159-1166 (1995). *

• Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Arch. Pediatr. Adolesc. Med. 152: 1132-1136 (1998).

• Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin. Rev. Allergy Immunol. 28: 115-133 (2005). *

• Tervaert JW, Van Hoek B, Koek G. Antineutrophil cytoplasmic antibodies in small-duct primary sclerosing cholangitis. Gastroenterology 136: 364 (2009). *

• Teubner A, Tillmann HL, Schuppan D, Gericke G, Manns MP, Stolzel U. Prevalence of circulating autoantibodies in healthy individuals. Med. Klin. (Munich) 97: 645-649 (2002).

• Teufel A, Worns M, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S. Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World J. Gastroenterol. 12: 5513-5516 (2006). *

• Toblli JE, Findor J, Sorda J, Bruch Igartua E, Hasenclever K, Collado HD. Latent distal renal tubular acidosis (dRTA) in primary biliary cirrhosis (PBC) and chronic autoimmune hepatitis (CAH). Acta Gastroenterol. Latinoam. 23: 235-238 (1993).

• Toda G, Ikeda Y, Hashimoto N, Yamazaki M, Torii M, Oka H. Liver cell membrane antibody detected by protein A and isolated rabbit liver plasma membrane in sera of patients with chronic liver diseases. Clin. Exp. Immunol. 54: 661-670 (1983). *

• Toh BH, Taylor R, Pollock W. F-actin reactive smooth muscle antibody in subjects with normal liver function. Pathology 41: 572-575 (2009).

• Tonini M, Vicini R, Cervio E, De Ponti F, De Giorgio R, Barbara G, Stanghellini V, Dellabianca A, Sternini C. 5-HT(7) receptors modulate peristalsis and accommodation in the guinea pig ileum. Gastroenterology 129: 1557-1566 (2005). *

• Tulloch-Reid MK, Boyne MS, Choo-Kang EG, Parkes RH, Wright-Pascoe RA, Barton EN, Wilks RJ, Palmer-Levy ML, Smikle MF. Autoantibodies in Caribbean youth with diabetes mellitus. Hum. Antibodies 17: 57-62 (2008).

• Uchida K, Okazaki K, Konishi Y, Ohana M, Takakuwa H, Hajiro K, Chiba T. Clinical analysis of autoimmune-related pancreatitis. Am. J. Gastroenterol. 95: 2788-2794 (2000). *

• Uhlig HH, Hultgren Hornquist E, Ohman Bache L, Rudolph U, Birnbaumer L, Mothes T. Antibody response to dietary and autoantigens in G alpha i2-deficient mice. Eur. J. Gastroenterol. Hepatol. 13: 1421-1429 (2001).

• Urganci N, Akyildiz B, Yildirmak Y, Ozbay G. A case of autoimmune hepatitis and autoimmune hemolytic anemia following hepatitis A infection. Turk. J. Gastroenterol. 14: 204-207 (2003). *

• van de Merwe JP. Interstitial cystitis and systemic autoimmune diseases. Nat. Clin. Pract. Urol. 4: 484-491 (2007).

• van Leeuwen DJ, Sood G, Ferrante D, Lazenby AJ, Sellers MJ. A 38-year-old African-American woman with an unusually rapid progression of "Primary Biliary Cirrhosis": a missed opportunity! Semin. Liver Dis. 22: 395-406 (2002).

• Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin. Immunopathol. 31: 421-435 (2009). *

• Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Ann. Ital. Med. Int. 11: 119-124 (1996).

• Vergani D, Mieli-Vergani G. Mechanisms of autoimmune hepatitis. Pediatr. Transplant. 8: 589-593 (2004). *

• Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Minerva Gastroenterol. Dietol. 50: 113-123 (2004).

• Vergani D, Mieli-Vergani G. Autoimmune serology in liver disease: methodology and interpretation. J. Gastroenterol. Hepatol. 19: S287-S289 (2004). *

• Vergani D, Mieli-Vergani G. Chapter 20. Autoimmune hepatitis. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 263-275 (2007). *

• Vergani D, Mieli-Vergani G. Autoimmune hepatitis: diagnostic and management challenges. J. Gastroenterol. Hepatol. 19: S388-S390 (2004). *

• Vierling JM. Primary biliary cirrhosis and autoimmune cholangiopathy. Clin. Liver Dis. 8: 177-194 (2004).

• Villalta D, Bizzaro N, Da Re M, Tozzoli R, Komorowski L, Tonutti E. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity 41: 105-110 (2008).

• Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, Klempnauer J, Nashan B, Manns MP, Strassburg CP. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin. Transplant. 18: 62-69 (2004). *

• von Boyen GB, Steinkamp M, Geerling I, Reinshagen M, Schafer KH, Adler G, Kirsch J. Proinflammatory cytokines induce neurotrophic factor expression in enteric glia: a key to the regulation of epithelial apoptosis in Crohn's disease. Inflamm. Bowel Dis. 12: 346-354 (2006).

• von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. 55: 133-166 (2003). *

• Wakefield D, Easter J, Robinson P, Graham D, Penny R. Chlamydial antibody crossreactivity with peripheral blood mononuclear cells of patients with ankylosing spondylitis: the role of HLA B27. Clin. Exp. Immunol. 63: 49-57 (1986). *

• Ward SC, Deniz K, Roayaie S, Qin L. Multifocal hepatocellular carcinoma and precancerous lesions in a patient with autoimmune hepatitis-related cirrhosis. Semin. Liver Dis. 28: 123-127 (2008).

• Washington MK. Autoimmune liver disease: overlap and outliers. Mod. Pathol. 20 Suppl. 1: S15-S30 (2007). *

• Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, Worman HJ, Gershwin ME, Podda M, Invernizzi P. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43: 1135-1144 (2006). *

• Wessler I, Bittinger F, Kamin W, Zepp F, Meyer E, Schad A, Kirkpatrick CJ. Dysfunction of the non-neuronal cholinergic system in the airways and blood cells of patients with cystic fibrosis. Life Sci. 80: 2253-2258 (2007). *

• Wieslawa AF, Lewinski A, Jochem J. Histamine in idiopathic inflammatory bowel diseases - not a standby player. Folia Med. Cracov. 46: 107-118 (2005).

• Wolak T, Kim H, Ren Y, Kim J, Vaziri ND, Nicholas SB. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int. 76: 32-43 (2009). *

• Wu CH, Xu XY, Tian GS, Yu YY. Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus. Zhonghua Yi Xue Za Zhi 86: 390-393 (2006).

• Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22: 1547-1559 (2002). *

• Yachha SK, Aggarwal R, Srinivas S, Srivastava A, Somani SK, Itha S. Antibody testing in Indian children with celiac disease. Indian J. Gastroenterol. 25: 132-135 (2006). *

• Yachha SK, Srivastava A, Chetri K, Saraswat VA, Krishnani N. Autoimmune liver disease in children. J. Gastroenterol. Hepatol. 16: 674-677 (2001). *

• Yan HP, Zhuang H, Liu YM, Feng X, Tan YF, Liu Y, Zhang X, Zhao CH. Immunological characteristics of primary biliary cirrhosis patients. Zhonghua Gan Zang Bing Za Zhi 13: 12-16 (2005).

• Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J. Autoimmune Dis. 1: 2 (2004). *

• Zamanou A, Tsirogianni A, Terzoglou C, Balafas A, Economidou I, Lymberi P. Anti-smooth muscle antibodies (ASMAs) and anti-cytoskeleton antibodies (ACTAs) in liver diseases: a comparison of classical indirect immunofluorescence with ELISA. J. Clin. Lab. Anal. 16: 194-201 (2002).

• Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G, Muratori L, Bianchi FB. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 25: 1105-1107 (1997). *

• Zelawski W, Witalinska-Labuzek J, Stadnicki A. A role of kallikrein-kinin system in gut diseases. Wiad. Lek. 58: 331-334 (2005).

• Zhang FK, Jia JD, Wang BE. Clinical evaluation of serum antimitochondrial antibody-negative primary biliary cirrhosis. Hepatobiliary Pancreat. Dis. Int. 3: 288-291 (2004). *

• Zhu GJ, Chen S, Mao Q, Wang YM. Clinical and pathological characterization of the overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis. Zhonghua Gan Zang Bing Za Zhi 13: 6-8 (2005).

Number of references = 344

www psc-literature.org